INmune Bio (NASDAQ:INMB) Earns Buy Rating from Analysts at Alliance Global Partners

Alliance Global Partners initiated coverage on shares of INmune Bio (NASDAQ:INMB) in a report issued on Monday, MarketBeat Ratings reports. The firm issued a buy rating and a $20.00 target price on the stock.

INMB has been the subject of a number of other research reports. Scotiabank assumed coverage on shares of INmune Bio in a report on Thursday, August 22nd. They issued a “sector outperform” rating and a $22.00 price target for the company. Raymond James started coverage on shares of INmune Bio in a research report on Friday, September 27th. They issued an “outperform” rating and a $18.00 target price on the stock.

INmune Bio Price Performance

Shares of NASDAQ:INMB opened at $5.22 on Monday. The stock has a market cap of $103.26 million, a P/E ratio of -2.72 and a beta of 1.85. The firm has a fifty day moving average price of $5.74 and a 200 day moving average price of $7.98. INmune Bio has a 1-year low of $4.78 and a 1-year high of $14.74.

INmune Bio (NASDAQ:INMB) last released its earnings results on Thursday, August 1st. The company reported ($0.50) EPS for the quarter, topping the consensus estimate of ($0.63) by $0.13. INmune Bio had a negative net margin of 26,333.59% and a negative return on equity of 103.56%. Sell-side analysts expect that INmune Bio will post -2.14 EPS for the current fiscal year.

Insider Buying and Selling at INmune Bio

In other news, CFO David J. Moss acquired 7,690 shares of the company’s stock in a transaction dated Thursday, September 12th. The shares were bought at an average price of $6.38 per share, for a total transaction of $49,062.20. Following the completion of the purchase, the chief financial officer now directly owns 1,275,869 shares of the company’s stock, valued at approximately $8,140,044.22. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In related news, CFO David J. Moss purchased 7,690 shares of the company’s stock in a transaction that occurred on Thursday, September 12th. The stock was acquired at an average price of $6.38 per share, for a total transaction of $49,062.20. Following the completion of the purchase, the chief financial officer now owns 1,275,869 shares in the company, valued at approximately $8,140,044.22. This represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO David J. Moss purchased 10,000 shares of the company’s stock in a transaction that occurred on Monday, September 30th. The stock was bought at an average price of $5.29 per share, with a total value of $52,900.00. Following the purchase, the chief financial officer now owns 1,285,869 shares of the company’s stock, valued at approximately $6,802,247.01. The trade was a 0.00 % increase in their position. The disclosure for this purchase can be found here. Insiders have acquired a total of 33,070 shares of company stock valued at $200,087 over the last ninety days. Corporate insiders own 35.20% of the company’s stock.

Institutional Trading of INmune Bio

Several institutional investors have recently added to or reduced their stakes in the business. CVI Holdings LLC acquired a new position in shares of INmune Bio during the second quarter valued at $5,260,000. Marshall Wace LLP grew its stake in shares of INmune Bio by 332.1% in the 2nd quarter. Marshall Wace LLP now owns 115,916 shares of the company’s stock valued at $1,022,000 after buying an additional 89,091 shares in the last quarter. Bank of New York Mellon Corp grew its stake in shares of INmune Bio by 124.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 58,600 shares of the company’s stock valued at $517,000 after buying an additional 32,511 shares in the last quarter. Westside Investment Management Inc. grew its stake in shares of INmune Bio by 31.8% in the 2nd quarter. Westside Investment Management Inc. now owns 45,340 shares of the company’s stock valued at $400,000 after buying an additional 10,950 shares in the last quarter. Finally, Fermata Advisors LLC boosted its position in INmune Bio by 25.2% during the third quarter. Fermata Advisors LLC now owns 42,730 shares of the company’s stock worth $230,000 after purchasing an additional 8,590 shares during the period. Institutional investors own 12.72% of the company’s stock.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.